Document Top

  • VEGF is a potent permeability factor

    VEGF is expressed throughout tumour development

        

     More

  • Flexibility to tackle altering tumour biology

    VEGF expression and the angiogenic switch

        

     More

  • Understanding tumour progression

    Precise VEGF inhibition with Avastin

        

     More

  • Avastin inhibits new and recurrent vessel growth

    Avastin inhibits new and recurrent vessel growth

        

     More

 
Case studies

Patient cases

Physicians share their experience and discuss  treatment options for patients with cancer.
The case presentations are designed to provide an insight into clinical practice and treatment decisions supported by trial data.

More

Educational webcasts

Educational webcasts

A series of webcasts highlighting some of the key learning points from scientific and clinical data.
Experienced physicians and scientists share their thoughts on the development of anticancer agents and discuss the options available for the treatment of cancer.

More

  • Expert perspectives in CRC

    Expert perspectives in CRC

    Impact of Avastin in CRC (Prof Eric van Cutsem)

    View

  • Avastin controls tumour growth

    Avastin controls tumour growth

    Avastin efficacy data in multiple tumour types and combination therapy.

    View

  • Expert perspective

    Expert perspective

    Targeting angiogenesis (Prof Joaquin Bellmunt)

    View

Watch more

  • Role of continued anti-VEGF therapy

    Role of continued anti-VEGF therapy

    A summary of data supporting the use of Avastin until disease progression to achieve maximum benefit (Dr Mark Kozloff)

    View

  • From tumour biology to biomarkers

    From tumour biology to biomarkers

    An insight into the evolving role of biomarkers for anti-angiogenesis therapy in oncology (Dr Donald McDonald)

    View

  • Clinical endpoints in oncology

    Clinical endpoints in oncology

    A discussion of clinical trial endpoints used in oncology trials and how these translate into patient benefit (Dr Artur Katz)

    View

Watch more

  • mBC patient case

    mBC patient case

    Triple-negative breast cancer patient with pre-existing controlled hypertension (Dr Paulo Cortes)

    View

  • CRC patient case

    CRC patient case

    A patient with colon adenocarcinoma with borderline resectable liver-only metastases (Dr Mark Kozloff)

    View

  • NSCLC patient case

    NSCLC patient case

    A patient with adenocarcinoma of the lung and pre-existing hypertension (Dr Monika Serke)

    View

Watch more

x

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.

OK Cancel